Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302

ConditionFabry Disease

Trial statusAvailable

Trial phaseNot listed

Trial typeExpanded Access

Biological sexNot listed

AgeNot listed

SponsorIdorsia Pharmaceuticals Ltd.

About this trial

This is a Post Trial Access program for patients with Fabry Disease who previously participated in the ID-069A302 (MODIFY OLE) trial and who were still enrolled in the study at the time the Sponsor decided to discontinue ID-069A302. The program is designed to provide continued access to lucerastat.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Lucerastat

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators

Idorsia Pharmaceuticals Ltd.

Lead sponsor

Source ClinicalTrials.gov